The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)
Abstract
Oral transmucosal fentanyl citrate (OTFC); Actiq) is a drug delivery formulation used for management of breakthrough cancer pain. Previous studies with open-label comparisons indicated OTFC was more effective than patients' usual opioid for breakthrough pain. The objective of this study was to compare OTFC and morphine sulfate immediate release (MSIR) for management of breakthrough pain in patients receiving a fixed scheduled opioid regimen. This double-blind, double-dummy, randomized, multiple crossover study was conducted at 19 US university- and community-based hospitals and clinics and comprised 134 adult ambulatory cancer patients. Patients were receiving a fixed scheduled opioid regimen equivalent to 60-1000 mg/day oral morphine or 50-300 microg/h transdermal fentanyl, were using a 'successful' MSIR dose (15-60 mg) as defined by entry criteria, and were experiencing 1-4 episodes of breakthrough pain per day. In open-label fashion, OTFC was titrated such that a single unit (200-1600 microg) provided adequate pain relief with acceptable side effects. Successfully titrated patients entered the double-blind phase of the study and received ten prenumbered sets of randomized capsules and oral transmucosal units. Five sets were the successful OTFC dose paired with placebo capsules, and five sets were placebo OTFC paired with capsules containing the successful MSIR dose. Patients took one set of study medication for each episode of target breakthrough pain. Pain intensity (PI), pain relief (PR) and global performance of medication (GP) scores were recorded. Pain intensity differences (PID) were calculated and 15-min PID was the primary efficacy variable. Adverse events were recorded. Sixty-nine percent of patients (93/134) found a successful dose of OTFC. OTFC yielded outcomes (PI, PID, and PR) at all time points that were significantly better than MSIR. GP also favored OTFC and more patients opted to continue with OTFC than MSIR following the study. Somnolence, nausea, constipation, and dizziness were the most common drug-associated side effects. In conclusion, OTFC was more effective than MSIR in treating breakthrough cancer pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the clinically important difference in pain outcome measures
Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L., & Strom, B. L. (2000) · Pain · doi:10.1016/s0304-3959(00)00339-0 · Cited by 1,071
Self-citationBreakthrough pain: definition, prevalence and characteristics
Portenoy, R. K., & Hagen, N. A. (1990) · Pain · doi:10.1016/0304-3959(90)90004-w · Cited by 933
Self-citationCancer pain relief and palliative care
Akinsanya, C. Y. (1992) · Nurse Education Today · doi:10.1016/0260-6917(92)90050-x · Cited by 692
Breakthrough pain: characteristics and impact in patients with cancer pain
Portenoy, R. K., Payne, D., & Jacobsen, P. (1999) · Pain · doi:10.1016/s0304-3959(99)00006-8 · Cited by 689
Self-citationPharmacokinetics, Pharmacodynamics, and Rational Opioid Selection
Shafer, S. L., & Varvel, J. R. (1991) · Anesthesiology · doi:10.1097/00000542-199101000-00010 · Cited by 587
Management of Cancer Pain, Clinical Practice Guideline No. 9.
ROSENBERG, M. B. (1996) · Anesthesia Progress · Cited by 262
Farrar, J. T., Cleary, J., Rauck, R., Busch, M., & Nordbrock, E. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.611 · Cited by 250
Self-citationAbsorption and Bioavailability of Oral Transmucosal Fentanyl Citrate
Streisand, J. B., Varvel, J. R., Stanski, D. R., Maire, L. L., Ashburn, M. A., Hague, B. I., Tarver, S. D., & Stanley, T. H. (1991) · Anesthesiology · doi:10.1097/00000542-199108000-00009 · Cited by 248
Affective and sensory dimensions of back pain
Leavitt, F. J., Garron, D. C., Whisler, W. W., & Sheinkop, M. B. (1977) · Pain · doi:10.1016/0304-3959(77)90139-7 · Cited by 118
Peak Plasma Concentrations After Oral Morphine
Collins, S., Faura, C. C., Moore, R. A., & McQuay, H. J. (1998) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(98)00094-3 · Cited by 109
Cited by
Portenoy, R. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60236-5 · Cited by 487
Self-citationDavies, A. N., Dickman, A., Reid, C., Stevens, A., & Zeppetella, G. (2009) · European Journal of Pain · doi:10.1016/j.ejpain.2008.06.014 · Cited by 482
Management of cancer pain: ESMO Clinical Practice Guidelines
Ripamonti, C. I., Santini, D., Maranzano, E., Berti, M., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds233 · Cited by 329
Double-phase hydrogel for buccal delivery of tramadol
Kamel, R., Mahmoud, A., & El-Feky, G. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2011.611807 · Cited by 28
Metadata
- Authors
- Coluzzi, P. H., Schwartzberg, L., Conroy, J. D., Charapata, S., Gay, M., Busch, M. A., Chavez, J., Ashley, J., Lebo, D., McCracken, M., & Portenoy, R. K.
- Venue
- Pain
- Published
- 2001-03
- Volume
- 91
- Issue
- 1
- Pages
- 123-130
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W1976427793
- Cited by
- 343
- References
- 11
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). https://app.cochat.ai/papers/10.1016/s0304-3959(00)00427-9
- The paper
- Coluzzi, P. H., Schwartzberg, L., Conroy, J. D., Charapata, S., Gay, M., Busch, M. A., Chavez, J., Ashley, J., Lebo, D., McCracken, M., & Portenoy, R. K. (2001). Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain. https://doi.org/10.1016/s0304-3959(00)00427-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.